Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial.
Publication
, Journal Article
Brooksbank, JA; Greene, SJ; Harris, HM; Stebbins, A; Fiuzat, M; Whellan, DJ; Alhanti, B; Kraus, WE; Piña, IL; O'Connor, CM; Mentz, RJ
Published in: Am Heart J
March 2021
Recognizing that body surface area (BSA) is a commonly used metric to inform medication dosing across fields of medicine, it is possible that patients with heart failure with reduced ejection fraction (HFrEF) with higher BSA may be more likely to tolerate higher doses of GDMT. Using the HF-ACTION trial, we examined (1) the relationship between BSA and achievement of target dosing of evidence-based beta-blocker and angiotensin-converting enzyme inhibitor (ACEI) therapy, and (2) the associations and interactions between target dosing, clinical outcomes, and BSA.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Am Heart J
DOI
EISSN
1097-6744
Publication Date
March 2021
Volume
233
Start / End Page
1 / 4
Location
United States
Related Subject Headings
- Stroke Volume
- Proportional Hazards Models
- Middle Aged
- Male
- Humans
- Heart Failure
- Female
- Drug Dosage Calculations
- Cause of Death
- Cardiovascular System & Hematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Brooksbank, J. A., Greene, S. J., Harris, H. M., Stebbins, A., Fiuzat, M., Whellan, D. J., … Mentz, R. J. (2021). Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial. Am Heart J, 233, 1–4. https://doi.org/10.1016/j.ahj.2020.11.003
Brooksbank, Jeremy A., Stephen J. Greene, Hailey M. Harris, Amanda Stebbins, Mona Fiuzat, David J. Whellan, Brooke Alhanti, et al. “Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial.” Am Heart J 233 (March 2021): 1–4. https://doi.org/10.1016/j.ahj.2020.11.003.
Brooksbank JA, Greene SJ, Harris HM, Stebbins A, Fiuzat M, Whellan DJ, et al. Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial. Am Heart J. 2021 Mar;233:1–4.
Brooksbank, Jeremy A., et al. “Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial.” Am Heart J, vol. 233, Mar. 2021, pp. 1–4. Pubmed, doi:10.1016/j.ahj.2020.11.003.
Brooksbank JA, Greene SJ, Harris HM, Stebbins A, Fiuzat M, Whellan DJ, Alhanti B, Kraus WE, Piña IL, O’Connor CM, Mentz RJ. Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial. Am Heart J. 2021 Mar;233:1–4.
Published In
Am Heart J
DOI
EISSN
1097-6744
Publication Date
March 2021
Volume
233
Start / End Page
1 / 4
Location
United States
Related Subject Headings
- Stroke Volume
- Proportional Hazards Models
- Middle Aged
- Male
- Humans
- Heart Failure
- Female
- Drug Dosage Calculations
- Cause of Death
- Cardiovascular System & Hematology